The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Cited by (1,105)

Items 901–1,000 of 1,105

1. Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer
   Tu Anh Nguyen, Brian James Kirsch, Ryoichi Asaka, Karim Nabi, Addison Quinones, Jessica Tan, Marjorie Justine Antonio, Felipe Camelo, Ting Li, Stephanie A. Nguyen et al. · 2019 · Cell Reports
2. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer
   Daniel James McGrail, Jeannine Garnett, Jun Yin, Hui Dai, David J. H. Shih, Truong Lam, Yang Li, Chaoyang Sun, Yongsheng Li, Rosemarie E. Schmandt et al. · 2020 · Cancer Cell
3. NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings
   Ömer An, Giovanni Marco Dall’Olio, Thanos P. Mourikis, Francesca D. Ciccarelli · 2015 · Nucleic Acids Research
4. Preclinical efficacy of MEK inhibition in Nras-mutant AML
   Michael R. Burgess, Eugene Hwang, Ari J. Firestone, Tannie Q. Huang, Jin Xu, Johannes A. Zuber, Natacha Bohin, Tiffany Wen, Scott C. Kogan, Kevin M. Haigis et al. · 2014 · Blood
5. RAB7 Controls Melanoma Progression by Exploiting a Lineage-Specific Wiring of the Endolysosomal Pathway
   Direna Alonso‐Curbelo, Erica Riveiro‐Falkenbach, Eva Pérez‐Guijarro, Metehan Cifdaloz, Panagiotis Karras, Lisa Osterloh, Diego Megı́as, Estela Cañón, Tonantzin G. Calvo, David Olmeda et al. · 2014 · Cancer Cell
6. ARID1a-DNA Interactions Are Required for Promoter Occupancy by SWI/SNF
   Ronald L. Chandler, Jennifer A. Brennan, Jonathan Cummings Schisler, Daniel Serber, Cam Patterson, Terry Magnuson · 2012 · Molecular and Cellular Biology
7. Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer
   Zhong Chen, Xun Lan, Dayong Wu, Benjamin D. Sunkel, Zhenqing Ye, Jiaoti Huang, Zhihua Liu, Steven K. Clinton, Victor X. Jin, Qianben Wang · 2015 · Nature Communications
8. DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer
   Soulafa Mamlouk, Liam Harold Childs, Daniela Ellen Aust, Daniel Heim, Friederike Melching, Cristiano Manuel Morais de Oliveira, Thomas A. Wolf, Pawel Durek, Dirk Schumacher, Hendrik Bläker et al. · 2017 · Nature Communications
9. Integrated proteogenomic characterization of urothelial carcinoma of the bladder
   Ning Xu, Zhenmei Yao, Guoguo Shang, Dingwei Ye, Haixing Wang, Hailiang Zhang, Yuanyuan Qu, Fujiang Xu, Yunzhi Wang, Zhaoyu Qin et al. · 2022 · Journal of Hematology & Oncology
10. Gene Expression Correlations in Human Cancer Cell Lines Define Molecular Interaction Networks for Epithelial Phenotype
    Kurt W. Kohn, Barry M. Zeeberg, William C. Reinhold, Yves G. Pommier · 2014 · PLoS ONE
11. Nannocystin A: an Elongation Factor 1 Inhibitor from Myxobacteria with Differential Anti‐Cancer Properties
    Philipp Krastel, Silvio P. Roggo, Markus Schirle, Nathan T. Ross, Francesca Perruccio, Peter Aspesi, Thomas Aust, Kathrin Buntin, David Estoppey, Brigitta Liechty et al. · 2015 · Angewandte Chemie International Edition
12. Widespread parainflammation in human cancer
    Dvir Aran, Audrey Lasry, Adar Zinger, Moshe Biton, Eli Pikarsky, Asaf Hellman, Atul Janardhan Butte, Yinon Ben‐Neriah · 2016 · Genome biology
13. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer
    Michiko Kodama, Takahiro Kodama, Justin Y. Newberg, Hiroyuki Katayama, Makoto Kobayashi, Samir Hanash, Kosuke Yoshihara, Zhubo Wei, Jean Ching-Yi Tien, Roberto Rangel et al. · 2017 · Proceedings of the National Academy of Sciences
14. GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network
    Motoki Takaku, Sara A. Grimm, John D. Roberts, Kaliopi Chrysovergis, Brian D. Bennett, Page Myers, L. Perera, Charles J. Tucker, Charles M. Perou, Paul A. Wade · 2018 · Nature Communications
15. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry
    Lena Katharina Freudenmann, Ana Marcu, Stefan Stevanović · 2018 · Immunology
16. Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data
    Ke Liu, Patrick A. Newbury, Benjamin Scott Glicksberg, Billy Zeng, Shreya Paithankar, Eran R. Andrechek, Bin Chen · 2019 · Nature Communications
17. CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism
    Andrea Piunti, Edwin R. Smith, Marc A. Morgan, Michal Ugarenko, Natalia Khalatyan, Kathryn A. Helmin, Caila Ryan, David C. Murray, Ryan A. Rickels, Bahar D. Yilmaz et al. · 2019 · Science Advances
18. Discovery of a selective inhibitor of doublecortin like kinase 1
    Fleur M. Ferguson, Behnam Nabet, Srivatsan Raghavan, Yan Liu, Alan L. Leggett, Miljan Kuljanin, Radha L. Kalekar, Annan Yang, Shuning He, Jinhua Wang et al. · 2020 · Nature Chemical Biology
19. Predicting and affecting response to cancer therapy based on pathway-level biomarkers
    Rotem Ben‐Hamo, Adi Jacob Berger, Nancy S. Gavert, Mendy L. Miller, Guy Pines, Roni Oren, Eli Pikarsky, Cyril H. Benes, Tzahi Neuman, Yaara Zwang et al. · 2020 · Nature Communications
20. Amino Acid Transporters as Targets for Cancer Therapy: Why, Where, When, and How
    Stefan Bröer · 2020 · International Journal of Molecular Sciences
21. Application of omics- and multi-omics-based techniques for natural product target discovery
    Hongwei Zhang, Chao Lv, Lijun Zhang, Xin Guo, Yiwen Shen, Dale G. Nagle, Yudong Zhou, Sanhong Liu, Weidong Zhang, Xin Luan · 2021 · Biomedicine & Pharmacotherapy
22. The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response
    Guangyu Wang, Dandan Xu, Zicheng Zhang, Xia Li, Jie Sun, Jie Sun, Xiaobo Li, Xiaobo Li, Meng Zhou, Tongsen Zheng · 2021 · npj Precision Oncology
23. Stromal fibroblasts shape the myeloid phenotype in normal colon and colorectal cancer and induce CD163 and CCL2 expression in macrophages
    Mira Stadler, Karoline Pudelko, Alexander Biermeier, Natalie Walterskirchen, Anthoula Gaigneaux, Claudia Weindorfer, Nathalie E. Harrer, Hagen Klett, Markus Hengstschläger, Julia B. Schüler et al. · 2021 · Cancer Letters
24. Drug-perturbation-based stratification of blood cancer
    Sascha Dietrich, Małgorzata Oleś, Junyan Lu, Leopold Sellner, Simon Anders, Britta Velten, Bian Wu, Jennifer Hüllein, Michelle S. Libério, Tatjana Walther et al. · 2017 · Kölner Universitäts PublikationsServer (Universität zu Köln)
25. An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway
    Garner, Thomas P., Reyna, Denis E., Priyadarshi, Amit, Chen, Hui-Chen, Li, Sheng, Wu, Yang, Ganesan, Yogesh Tengarai, Malashkevich, Vladimir N., Cheng, Emily H., Gavathiotis, Evripidis · 2016 · Molecular Cell
26. Targeting the histone orthography of cancer: drugs for writers, erasers and readers
    Laia Simó‐Riudalbas, Manel Esteller · 2014 · British Journal of Pharmacology
27. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
    Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm, Robin A. Fairhurst, Michael Kiffe, Dario Sterker, Mario Centeleghe, Markus Wartmann, Jacqueline Kinyamu-Akunda et al. · 2019 · Molecular Cancer Therapeutics
28. Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
    Fred Harbinski, Vanessa J. Craig, Sneha Sanghavi, Douglas A. Jeffery, Lijuan Liu, Kelly Ann Sheppard, Sabrina Wagner, Christelle Stamm, Andreas Buneß, Christian Chatenay‐Rivauday et al. · 2012 · Cancer Discovery
29. ZEB 1‐regulated inflammatory phenotype in breast cancer cells
    Akihiro Katsura, Yusuke Tamura, Satoshi Hokari, Mayumi Harada, Masato Morikawa, Tsubasa Sakurai, Kei Takahashi, Anna Mizutani, Jun Nishida, Yuichiro Yokoyama et al. · 2017 · Molecular Oncology
30. BioMuta and BioXpress: mutation and expression knowledgebases for cancer biomarker discovery
    Hayley Dingerdissen, John Torcivia-Rodriguez, Yu Hu, Ting-Chia Chang, Raja Mazumder, Robel Kahsay · 2017 · Nucleic Acids Research
31. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets
    Juan Bayo, Esteban Juan Fiore, Luciana M. Domínguez, Alejandrina Real, Mariana Malvicini, Manglio Rizzo, Catalina Atorrasagasti, Mariana Gabriela García, Josepmaria Argemí, Elisabeth D. Martínez et al. · 2019 · Journal of Hepatology
32. Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution
    Roxane M. Pommier, Amélien Sanlaville, Laurie Tonon, Janice Kielbassa, Emilie Thomas, Anthony Ferrari, Anne-Sophie Sertier, Frédéric Hollande, Pierre Martinez, Agnès Tissier et al. · 2020 · Nature Communications
33. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
    Marcel Alexander Heinrich, Ahmed M. R. H. Mostafa, Jennifer P. Morton, Lukas J.A.C. Hawinkels, Jai Prakash · 2021 · Advanced Drug Delivery Reviews
34. Cell lines battle cancer
    John N. Weinstein · 2012 · Nature
35. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors
    Fang Li, Hung The Huynh, Xiaoyan Li, David A. Ruddy, Youzhen Wang, Richard Ong, Pierce K. H. Chow, Shumei Qiu, Angela Tam, Daniel P. Rakiec et al. · 2015 · Cancer Discovery
36. Hedgehog–GLI Signaling Inhibition Suppresses Tumor Growth in Squamous Lung Cancer
    Lingling Huang, Vonn Walter, David Neil Hayes, Mark W. Onaitis · 2014 · Clinical Cancer Research
37. Signaling Network Assessment of Mutations and Copy Number Variations Predict Breast Cancer Subtype-Specific Drug Targets
    Naif Zaman, Lei Li, Maria Luz Jaramillo, Zhanpeng Sun, Chabane Tibiche, Myriam Banville, Catherine Collins, Mark A. Trifiro, Miltiadis Paliouras, André Nantel et al. · 2013 · Cell Reports
38. Multitask learning improves prediction of cancer drug sensitivity
    Han Yuan, Ivan Paskov, Hristo S. Paskov, Alvaro J. González, Christina S. Leslie · 2016 · Scientific Reports
39. Drug Response Prediction as a Link Prediction Problem
    Zachary Stanfield, Mustafa Coşkun, Mehmet Koyutürk · 2017 · Scientific Reports
40. Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
    Ram Ajore, David M. Raiser, Marie Ellen McConkey, Magnus Jöud, Bernd Boidol, Brenton G. Mar, Gordon Saksena, David M. Weinstock, Scott A. Armstrong, Steven Robert Ellis et al. · 2017 · EMBO Molecular Medicine
41. Comparative Study of Transcriptomics-Based Scoring Metrics for the Epithelial-Hybrid-Mesenchymal Spectrum
    Priyanka Chakraborty, Jason Thomas George, Shubham Tripathi, Herbert Levine, Mohit Kumar Jolly · 2020 · Frontiers in Bioengineering and Biotechnology
42. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities
    Caitlin A. Nichols, William J. Gibson, Meredith S. Brown, Jack A. Kosmicki, John P. Busanovich, Hope Y. Wei, Laura M. Urbanski, Naomi Currimjee, Ashton C. Berger, Galen F. Gao et al. · 2020 · Nature Communications
43. Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies
    Andrew M. K. Law, Laura Rodríguez de la Fuente, Thomas James Grundy, Guocheng Fang, Fátima Valdés‐Mora, David Gallego‐Ortega · 2021 · Frontiers in Oncology
44. DrugMap: A quantitative pan-cancer analysis of cysteine ligandability
    Mariko Takahashi, Harrison Byron Chong, Siwen Zhang, Tzu-yi Yang, Matthew J. Lazarov, Stefan Andrew Harry, Michelle Maynard, Brendan J. Hilbert, Ryan D. White, Heather E. Murrey et al. · 2024 · Cell
45. Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine
    Ólafur Andri Stefánsson, Manel Esteller · 2013 · American Journal Of Pathology
46. Intratumor heterogeneity alters most effective drugs in designed combinations
    Boyang Zhao, Michael T. Hemann, Douglas A. Lauffenburger · 2014 · Proceedings of the National Academy of Sciences
47. Neurodevelopmental origins of bipolar disorder: iPSC models
    K. Sue O’Shea, Melvin G. McInnis · 2015 · Molecular and Cellular Neuroscience
48. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response
    Mike Nickerson, N Witte, Kate M. Im, Sevilay Turan, Charles R. Owens, K Misner, Shirley X. Tsang, Zhiming Cai, Song Wu, Michael C. Dean et al. · 2016 · Oncogene
49. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid
    Xian‐Yang Qin, Harukazu Suzuki, Masao Honda, Hikari Okada, Shuichi Kaneko, Ikuyo Inoue, Etsuko Ebisui, Kosuke Hashimoto, Piero Carninci, Keita Kanki et al. · 2018 · Proceedings of the National Academy of Sciences
50. The LL-100 panel: 100 cell lines for blood cancer studies
    Hilmar Quentmeier, Claudia Pommerenke, Wilhelm Gerhard Dirks, Sonja Eberth, Max Koeppel, Roderick A.F. MacLeod, Stefan Nagel, Klaus G. Steube, Cord C. Uphoff, Hans Günter Drexler · 2019 · Scientific Reports
51. Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias
    Laura Hinze, Maren Pfirrmann, Salmaan Karim, James Degar, Connor McGuckin, Divya S. Vinjamur, Joshua R. Sacher, Kristen E. Stevenson, Donna S Neuberg, Esteban A. Orellana et al. · 2019 · Cancer Cell
52. Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells
    Emarndeena Haji Cheteh, Victoria Sarne, Sophia Ceder, Julie Bianchi, Martin Augsten, Helene Rundqvist, Lars Egevad, Arne Östman, Klas G. Wiman · 2020 · Cell Death Discovery
53. Multiplex enCas12a screens detect functional buffering among paralogs otherwise masked in monogenic Cas9 knockout screens
    Merve Dede, Megan E. McLaughlin, Eiru Kim, Traver Hart · 2020 · Genome biology
54. Genome-wide analysis of somatic noncoding mutation patterns in cancer
    Felix Dietlein, Alex B. Wang, Christian R. Fagre, Anran Tang, Nicolle J.M. Besselink, Edwin P. J. G. Cuppen, Chunliang Li, Shamil R. Sunyaev, James T. Neal, Eliezer M. Van Allen · 2022 · Science
55. Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics
    Sonam Bhatia, Melissa Kramer, Suzanne Russo, Payal Naik, Gayatri Arun, Kyle Brophy, Peter Andrews, Cheng Fan, Charles M. Perou, Jonathan B. Preall et al. · 2022 · Cancer Research
56. xCell: Digitally portraying the tissue cellular heterogeneity landscape
    Dvir Aran, Zicheng Hu, Atul Janardhan Butte · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
57. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer
    Robert A. Beckman, Gunter S. Schemmann, Chen‐Hsiang Yeang · 2012 · Proceedings of the National Academy of Sciences
58. Cellular and molecular effects of the mTOR inhibitor everolimus
    Uttara Saran, Michelangelo Foti, Jean‐François Dufour · 2015 · Clinical Science
59. Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer
    Jonathan T. Goldstein, Ashton C. Berger, Juliann Shih, Fujiko F. Duke, Laura Furst, David J. Kwiatkowski, Andrew D. Cherniack, Matthew M. Meyerson, Craig A. Strathdee · 2017 · Cancer Research
60. Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment
    Nathan Ungerleider, Sonia G. Rao, Ashkan Shahbandi, Douglas Yee, Tianhua Niu, Wesley D. Frey, James G. Jackson · 2018 · Breast Cancer Research
61. Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
    Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, Martine B.W. Prinsen, Jos de Man, Yoshinori Tanizawa, Yusuke Kawase, Kohichiro Yoshino, Rogier C. Buijsman, Guido J.R. Zaman · 2014 · PLoS ONE
62. JACKS: joint analysis of CRISPR/Cas9 knockout screens
    Felicity R. Allen, Fiona M. Behan, Anton Khodak, Francesco Iorio, Kosuke Yusa, Mathew J. Garnett, Leopold Parts · 2019 · Genome Research
63. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma
    Anais Laforest, Thomas Aparicio, Aziz Zaanan, Fabio Pittella-Silva, Audrey Didelot, A. Desbeaux, Delphine Le Corre, Léonor Benhaïm, Karine Pallier, Daniela Ellen Aust et al. · 2014 · European Journal of Cancer
64. Self-seeding microwell chip for the isolation and characterization of single cells
    Joost F. Swennenhuis, Arjan G.J. Tibbe, Michiel Stevens, Madhumohan Rao Katika, Joost van Dalum, Hien Duy Tong, Cees J. M. van Rijn, Leon W.M.M. Terstappen · 2015 · Lab on a Chip
65. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
    Sai-Wen Tang, Sven Bilke, Liang Cao, Junko Murai, Fabrício Garmus Sousa, Mihoko Yamade, Vinodh N. Rajapakse, Sudhir Varma, Lee J. Helman, Javed Iqbal Khan et al. · 2015 · Clinical Cancer Research
66. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read‐outs
    Vítor Espirito Santo, Sofia P. Rebelo, Marta F Estrada, Paula M. Alves, Erwin R. Boghaert, Catarina Brito · 2016 · Biotechnology Journal
67. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway
    S. C. Tripathi, Johannes Francois Fahrmann, Müge Çeliktaş, Mitzi Aguilar, Kieren D. Marini, Mohit Kumar Jolly, Hiroyuki Katayama, Hong Wang, Eunice N. Murage, Jennifer B. Dennison et al. · 2017 · Cancer Research
68. NDRG1 regulates neutral lipid metabolism in breast cancer cells
    Christopher J. Sevinsky, Faiza Khan, Leila Kokabee, Anza Darehshouri, Krishna Rao Maddipati, Douglas S. Conklin · 2018 · Breast Cancer Research
69. PAX5 loss imposes a reversible differentiation block in b-progenitor acute lymphoblastic leukemia
    Grace Liu, Luisa Cimmino, Julian Jude, Yifang Hu, Matthew T. Witkowski, Mark D. McKenzie, Mutlu Kartal‐Kaess, Sarah A. Best, Laura Tuohey, Yang Liao et al. · 2014 · Experimental Hematology
70. Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation
    Cheryl Carson, Pichai Raman, Jennifer Tullai, Lei Xu, Martin Hénault, Emily Thomas, Sarita W. Yeola, Jianmin Lao, Mark J. McPate, Jan Martin Verkuyl et al. · 2015 · PLoS ONE
71. Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
    Min H. Kang, Jing Wang, Monish Ram Makena, Joo-Sang Lee, Nancy Paz, Connor P. Hall, Michael Meansup Song, Ruben I. Calderon, Riza E. Cruz, Ashly Hindle et al. · 2015 · Clinical Cancer Research
72. NOTCH-mediated non-cell autonomous regulation of chromatin structure during senescence
    Parry, Aled J., Hoare, Matthew, Bihary, Dóra, Hänsel-Hertsch, Robert, Smith, Stephen, Tomimatsu, Kosuke, Mannion, Elizabeth, Smith, Amy, D’Santos, Paula, Russell, I. Alasdair et al. · 2018 · Nature Communications
73. Targeted Degradation of SLC Transporters Reveals Amenability of Multi-Pass Transmembrane Proteins to Ligand-Induced Proteolysis
    Bensimon, Ariel, Pizzagalli, Mattia D., Kartnig, Felix, Dvorak, Vojtech, Essletzbichler, Patrick, Winter, Georg E., Superti-Furga, Giulio · 2020 · Cell Chemical Biology
74. Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions
    Mikhail Shugay, Iñigo Ortiz de Mendíbil, J.L. Vizmanos, Francisco Javier Novo · 2013 · Bioinformatics
75. Drug susceptibility prediction against a panel of drugs using kernelized Bayesian multitask learning
    Mehmet Gönen, Adam A. Margolin · 2014 · Bioinformatics
76. High-resolution network biology: connecting sequence with function
    Colm J. Ryan, Peter Cimermančič, Zachary A. Szpiech, Andrej Šali, Ryan D. Hernandez, Nevan J. Krogan · 2013 · Nature Reviews Genetics
77. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
    James Campbell, Colm J. Ryan, Rachel Brough, Ilirjana Bajrami, Helen N. Pemberton, Irene Yu-Shing Chong, Sara Costa-Cabral, Jessica R. Frankum, Aditi Gulati, Harriet Holme et al. · 2016 · Cell Reports
78. The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells
    Elizabeth A. Stanford, Zhongyan Wang, Olga Novikov, Francesca Mulas, Esther Landesman‐Bollag, Stefano Monti, Brenden W. Smith, David C. Seldin, George J. Murphy, David H. Sherr · 2016 · BMC Biology
79. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer
    Kelsie L. Thu, Jennifer Silvester, Mitchell J. Elliott, Wail Ba-Alawi, M. H. Duncan, Andrea C. Elia, Arvind Singh Mer, Petr Smirnov, Zhaleh Safikhani, Benjamin Haibe‐Kains et al. · 2018 · Proceedings of the National Academy of Sciences
80. Transcriptional effects of copy number alterations in a large set of human cancers
    Arkajyoti Bhattacharya, Rico D. Bense, Carlos G. Urzúa-Traslaviña, Elisabeth G.E. de Vries, Marcel A.T.M. van Vugt, Rudolf S.N. Fehrmann · 2020 · Nature Communications
81. Breeze: an integrated quality control and data analysis application for high-throughput drug screening
    Potdar, Swapnil, Ianevski, Aleksandr, Mpindi, John-Patrick, Bychkov, Dmitrii, Fiere, Clément, Ianevski, Philipp, Yadav, Bhagwan, Wennerberg, Krister, Aittokallio, Tero, Kallioniemi, Olli et al. · 2020 · Bioinformatics
82. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma
    Sean P. Martin, Valerie E. Fako, Hien T. Dang, Dana A. Dominguez, Subreen A. Khatib, Lichun Ma, Haiyang Wang, Wei Zheng, Xin Wei Wang · 2020 · Journal of Experimental & Clinical Cancer Research
83. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine
    Valentin Van den Bossche, Hannah Zaryouh, Marianela Vara-Messler, Julie Vignau, Jean‐Pascal Machiels, An Wouters, Sandra Schmitz, Cyril Corbet · 2022 · Drug Resistance Updates
84. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma
    Alyssa L. Kennedy, Mounica Vallurupalli, Liying Chen, Brian D. Crompton, Glenn S. Cowley, Francisca Vázquez, Barbara A. Weir, Aviad Tsherniak, Sudha Parasuraman, Sunkyu Kim et al. · 2015 · Oncotarget
85. A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines
    Sebastian Boegel, Martin Löwer, Thomas Bukur, Uğur Şahin, John C. Castle · 2014 · OncoImmunology
86. Paralog buffering contributes to the variable essentiality of genes in cancer cell lines
    De Kegel, Barbara, Ryan, Colm J. · 2019 · PLOS Genetics
87. UMI-4C for quantitative and targeted chromosomal contact profiling
    Omer Schwartzman, Zohar Mukamel, Noa Oded Elkayam, Pedro Olivares‐Chauvet, Yaniv Lubling, Gilad Landan, Shai Izraeli, Amos Tanay · 2016 · Nature Methods
88. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility
    Erik S. Knudsen, Uthra Balaji, Brian K. Mannakee, Paris J. Vail, Cody R. Eslinger, Christopher Moxom, John C. Mansour, Agnieszka Katarzyna Witkiewicz · 2017 · Gut
89. Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines
    Tahlita C.M. Zuiverloon, Florus C. de Jong, James C. Costello, Dan Theodorescu · 2018 · Bladder Cancer
90. A cloud-based workflow to quantify transcript-expression levels in public cancer compendia
    PJ Tatlow, Stephen Piccolo · 2016 · Scientific Reports
91. Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
    Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha · 2019 · The Oncologist
92. Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens
    Emanuel Gonçalves, Aldo Segura‐Cabrera, Clare Pacini, Gabriele Picco, Fiona M. Behan, Patricia Jaaks, Elizabeth A. Coker, Donny van der Meer, Andrew S. Barthorpe, Howard W. Lightfoot et al. · 2020 · Molecular Systems Biology
93. The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers
    Jun Qian, Mohamed Hassanein, Megan D. Hoeksema, Bradford K. Harris, Yong Zou, Heidi Chen, Lu Wang, Rosana Eisenberg, Jing Wang, Allan V. Espinosa et al. · 2015 · Proceedings of the National Academy of Sciences
94. Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
    Lawrence N. Kwong, Michael A. Davies · 2013 · Clinical Cancer Research
95. EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma
    Hongping Xia, Jianxiang Chen, Ming Shi, Hengjun Gao, Karthik Sekar, Veerabrahma Pratap Seshachalam, London Lucien Ooi, Kam Man Hui · 2015 · Journal of Hepatology
96. Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
    Christos Hatzis, Philippe Lucien Bedard, Nicolai J. Birkbak, Andrew H. Beck, Hugo J.W.L. Aerts, David F. Stern, Leming M. Shi, Robert C. Clarke, John F Quackenbush, Benjamin Haibe‐Kains · 2014 · Cancer Research
97. Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy
    Leila Haery, Ryan C. Thompson, Thomas D. Gilmore · 2015 · Genes & Cancer
98. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling
    Bin Chen, Wei Wei, Li Ma, Bin Yang, Ryan M. Gill, Mei‐Sze Chua, Atul Janardhan Butte, Samuel K. So · 2017 · Gastroenterology
99. Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient
    Nam Nhut Phan, Chih‐Yang Wang, Kuan-Lun Li, Chien‐Fu Chen, Chung-Chieh Chiao, Han-Gang Yu, Pung-Ling Huang, Yen-Chang Lin · 2018 · Oncotarget
100. Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability
     Kenichi Iwai, Masahiro Yaguchi, Kazuho Nishimura, Yukiko Yamamoto, Toshiya Tamura, Daisuke Nakata, Ryo Dairiki, Yoichi Kawakita, Ryo Mizojiri, Yoshiteru Ito et al. · 2018 · EMBO Molecular Medicine